GPCR

MKT CAP:$3B

Structure Therapeutics Inc.

Market Cap

$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$46.50-$21.62 (-31.74%)

Apr 22, 2026

Company Details

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral an...

CEO

Raymond C. Stevens

IPO Date

Feb 3, 2023

Website

structuretx.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$141M

EPS (Diluted)

-$2.40

Free Cash Flow

-$226M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Feb 26, 2026

$0EPS -$2.40

Q4 2025

Feb 26, 2026

$0EPS $0.60

Q3 2025

Nov 6, 2025

$0EPS -$1.11

Q2 2025

Aug 6, 2025

$0EPS -$1.08

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$13M
Q2 22	$0	$0	-$14M
Q3 22	$0	$0	-$13M
Q1 23	$0	$0	-$20M
Q3 23	$0	$0	-$26M
Q4 23	$0	$0	-$31M
Q1 24	$0	$0	-$32M
Q2 24	$0	$0	-$33M
Q3 24	$0	$0	-$46M
Q4 24	$0	$0	-$47M
Q1 25	$0	$0	-$56M
Q2 25	$0	$0	-$70M
Q3 25	$0	$0	-$74M
Q4 25	$0	$0	$24M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$14M	-$14M
Q2 22	-$10M	-$10M
Q3 22	-$10M	-$11M
Q1 23	-$20M	-$20M
Q3 23	-$21M	-$21M
Q4 23	-$22M	-$23M
Q1 24	-$34M	-$34M
Q2 24	-$26M	-$27M
Q3 24	-$20M	-$20M
Q4 24	-$36M	-$36M
Q1 25	-$52M	-$53M
Q2 25	-$55M	-$55M
Q3 25	-$51M	-$53M
Q4 25	-$64M	-$66M

Capital Expenditures

Quarter	CapEx
Q1 22	$65.0K
Q2 22	$53.0K
Q3 22	$72.0K
Q1 23	$0
Q3 23	$820.0K
Q4 23	$1M
Q1 24	$162.0K
Q2 24	$427.0K
Q3 24	$685.0K
Q4 24	$16.0K
Q1 25	$314.0K
Q2 25	$232.0K
Q3 25	$2M
Q4 25	$1M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 23	—	+101.9%
Q4 23	—	+122.0%
Q1 24	—	+152.2%
Q2 24	—	+69.6%
Q3 24	—	+75.3%
Q4 24	—	+51.8%
Q1 25	—	+75.9%
Q2 25	—	+111.5%
Q3 25	—	+61.0%
Q4 25	—	-151.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$620.0K	—
Q2 22	$643.0K	—
Q3 22	$628.0K	—
Q1 23	$3M	—
Q3 23	$2M	—
Q4 23	$2M	—
Q1 24	$3M	—
Q2 24	$4M	—
Q3 24	$6M	—
Q4 24	$6M	—
Q1 25	$6M	—
Q2 25	$8M	—
Q3 25	$7M	—
Q4 25	$8M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$8M	$4M
Q2 22	$10M	$4M
Q3 22	$9M	$4M
Q1 23	$13M	$7M
Q3 23	$18M	$9M
Q4 23	$20M	$11M
Q1 24	$21M	$11M
Q2 24	$22M	$11M
Q3 24	$33M	$13M
Q4 24	$33M	$14M
Q1 25	$43M	$13M
Q2 25	$55M	$16M
Q3 25	$59M	$15M
Q4 25	$69M	$18M

War Chest

Quarter	Cash	Short-term Investments	Total
Q3 22	$28M	$75M	$103M
Q4 22	$26M	$65M	$91M
Q1 23	$126M	$114M	$241M
Q2 23	$41M	$184M	$225M
Q3 23	$51M	$155M	$205M
Q4 23	$130M	$338M	$467M
Q1 24	$98M	$339M	$436M
Q2 24	$382M	$545M	$927M
Q3 24	$172M	$743M	$915M
Q4 24	$170M	$714M	$884M
Q1 25	$152M	$685M	$837M
Q2 25	$147M	$639M	$786M
Q3 25	$103M	$696M	$799M
Q4 25	$800M	$647M	$1.4B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	37M	—	—
Q2 22	37M	0.0%	—
Q3 22	39M	+6.9%	—
Q1 23	37M	-4.3%	—
Q3 23	38M	+2.4%	+4.7%
Q4 23	46M	+21.1%	+26.8%
Q1 24	47M	+0.4%	+19.0%
Q2 24	49M	+6.1%	+32.0%
Q3 24	57M	+15.8%	+49.3%
Q4 24	57M	+0.1%	+23.4%
Q1 25	57M	+0.1%	+23.1%
Q2 25	58M	+1.0%	+17.2%
Q3 25	58M	+1.0%	+2.2%
Q4 25	59M	+1.2%	+3.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q1 23	$0	68
Q3 23	$0	68
Q4 23	$0	93
Q1 24	$0	93
Q2 24	$0	93
Q3 24	$0	93
Q4 24	$0	163
Q1 25	$0	163
Q2 25	$0	163
Q3 25	$0	163
Q4 25	$0	200K

Revenue / Employee